Isepamicin in intensive care unit patients with nosocomial pneumonia: Population pharmacokinetic-pharmacodynamic study

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 1, 1999, Pages 99-108

  Tod, M ^a   Minozzi, C ^b   Beaucaire, G ^c   Ponsonnet, D ^b   Cougnard, J ^b   Petitjean, O ^a  

^a AVICENNE HOSPITAL   (France)

^b Schering Plough   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CREATININE; IMIPENEM; ISEPAMICIN;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CORRELATION FUNCTION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NEPHROTOXICITY; PNEUMONIA; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BAYES THEOREM; CREATININE; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENTAMICINS; HUMANS; INTENSIVE CARE UNITS; KIDNEY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 0032855416     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.1.99     Document Type: Article

References (29)

1. Craig, W. A. (1995). Once-daily versus multiple-daily dosing of aminoglycosides. Journal of Chemotherapy 7, Suppl. 2, 47-52.
2. Ali, M. Z. & Goetz, M. B. (1997). A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clinical Infectious Diseases 24, 796-809.
3. Keating, M. J., Bodey, G. P., Valdivieso, M. & Rodriguez, V. (1979). A randomized comparative trial of three aminoglycosides -comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine 58, 159-70.
4. Klastersky, J., Daneau, D., Swings, G. & Weerts, D. (1974). Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. Journal of Infectious Diseases 129, 187-93.
5. Deziel-Evans, L. M., Murphy, J. E. & Job, M. L. (1986). Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clinical Pharmacy 5, 319-24.
6. Moore, R. D., Lietman, P. S. & Smith, C. R. (1987). Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 155, 93-9.
7. Sculier, J. P. & Klastersky, J. (1984). Significance of serum bactericidal activity in Gram-negative bacillary bacteremia in patients with and without granulocytopenia. American Journal of Medicine 76, 429-35.
8. Vogelman, B., Gudmunsson, S., Legett, J., Turnidge, J., Ebert, S. & Craig, W. A. (1988). Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 158, 831-47.
9. Schentag, J. J., Cerra, F. B. & Plaut M. E. (1982). Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrobial Agents and Chemotherapy 21, 721-6.
10. Matzke, G. R., Lucarotti, R. L. & Shapiro, H. S. (1983). Controlled comparison of gentamicin and tobramycin nephrotoxicity. American Journal of Nephrology 3, 11-7.
11. Lerner, S. A., Schmitt, B. A., Seligsohn, R. & Matz, G. J. (1986). Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. American Journal of Medicine 80, 98-104.
12. ter Braak, E. W., de Vries, P. J., Bouter, K. P., van der Vegt, S. G., Dorrestein, G. C., Mortier, J. W. et al. (1990). Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. American Journal of Medicine 89, 58-66.
13. McCormack, J. P. & Jeweson, P. J. (1992). A critical reevaluation of the 'therapeutic range' of aminoglycosides. Clinical Infectious Diseases 14, 320-39.
14. Sheiner, L. B. & Ludden, T. M. (1992). Population pharmacokinetics/dynamics. Annual Reviews in Pharmacology and Toxicology 32, 185-209.
15. Maitre, P. O., Bührer, M., Thomson, D. & Stanski, D. R. (1991). A three step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. Journal of Pharmacokinetics and Biopharmaceutics 19, 377-84.
16. Mandema, J. W., Verotta, D. & Sheiner, L. B. (1992). Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. Journal of Pharmacokinetics and Biopharmaceutlcs 20, 511-28.
17. White, D. B., Walawander, C. A., Liu, D. Y. & Grasela, T. H. (1992). Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. Journal of Pharmacokinetics and Biopharmaceutics 20, 295-313.
18. Wagner, J. G. (1993). Pharmacokinetics for the Pharmaceutical Scientist. Technomic, Lancaster, PA.
19. Beal, S. L. & Sheiner, L. B. (1992). NONMEM user's guides. NONMEM Project Group, University of California, San Francisco, CA.
20. Cockcroft, D. W. & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-47.
21. Tod, M., Padoin, C., Minozzi, C., Cougnard, J. & Petitjean, O. (1996). Population pharmacokinetic study of isepamicin with intensive care unit patients. Antimicrobial Agents and Chemotherapy 40, 983-7.
22. Fuhs, D. W., Mann, H. J., Kubajak, C. A. M. & Cerra, F. B. (1988). Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients. Clinical Pharmacy 7, 207-13.
23. Barr, W. H., Colucci, R., Radwanski, E., Zampaglione, N., Cuther, D., Lin, C. C. et al. (1995). Pharmacokinetics of isepamicin. Journal of Chemotherapy 7, Suppl. 2, 53-61.
24. Xiong, Y., Caillon, J., Kergueris, M. F., Drugeon, H., Baron, D., Potel, G. et al.(1997). Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycodes and killing kinetics in a rabbit endocarditis model. Antimicrobial Agents and Chemotherapy 41, 823-6.
25. Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham M. C. & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
26. Hyatt, J. M., Mc Kinnon, P. S., Zimmer, G. S. & Schentag, J. J. (1995). The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clinical Pharmacokinetics 28, 143-60.
27. Hyatt, J. M., Nix, D. E. & Schentag, J. J. (1994). Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa for which MIC's are similar. Antimicrobial Agents and Chemotherapy 38, 2730-7.
28. Boucher, B. A., Coffrey, B. C., Kuhl, D. A., Tolley, E. A. & Fabian, T. C. (1990). Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides. American Journal of Surgery 160, 473-80.
29. Flint, L. M., Gott, J., Short, L., Richardson, J. D. & Polk, H. C. (1985). Serum level monitoring of aminoglycoside antibiotics. Limitations in intensive care unit-related bacterial pneumonia. Archives of Surgery 120, 99-103.